JP2018515106A5 - - Google Patents

Download PDF

Info

Publication number
JP2018515106A5
JP2018515106A5 JP2017559428A JP2017559428A JP2018515106A5 JP 2018515106 A5 JP2018515106 A5 JP 2018515106A5 JP 2017559428 A JP2017559428 A JP 2017559428A JP 2017559428 A JP2017559428 A JP 2017559428A JP 2018515106 A5 JP2018515106 A5 JP 2018515106A5
Authority
JP
Japan
Prior art keywords
gene encoding
promoter
genetically engineered
gene
pal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017559428A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018515106A (ja
JP6843768B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/032562 external-priority patent/WO2016183531A1/en
Publication of JP2018515106A publication Critical patent/JP2018515106A/ja
Publication of JP2018515106A5 publication Critical patent/JP2018515106A5/ja
Priority to JP2021027597A priority Critical patent/JP7245271B2/ja
Application granted granted Critical
Publication of JP6843768B2 publication Critical patent/JP6843768B2/ja
Priority to JP2023037515A priority patent/JP7592777B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017559428A 2015-05-13 2016-05-13 高フェニルアラニン血症を低減させるように操作された細菌 Active JP6843768B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021027597A JP7245271B2 (ja) 2015-05-13 2021-02-24 高フェニルアラニン血症を低減させるように操作された細菌
JP2023037515A JP7592777B2 (ja) 2015-05-13 2023-03-10 高フェニルアラニン血症を低減させるように操作された細菌

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562161137P 2015-05-13 2015-05-13
US62/161,137 2015-05-13
US201562256052P 2015-11-16 2015-11-16
US62/256,052 2015-11-16
PCT/US2016/032562 WO2016183531A1 (en) 2015-05-13 2016-05-13 Bacteria engineered to reduce hyperphenylalaninemia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021027597A Division JP7245271B2 (ja) 2015-05-13 2021-02-24 高フェニルアラニン血症を低減させるように操作された細菌

Publications (3)

Publication Number Publication Date
JP2018515106A JP2018515106A (ja) 2018-06-14
JP2018515106A5 true JP2018515106A5 (cg-RX-API-DMAC7.html) 2019-06-13
JP6843768B2 JP6843768B2 (ja) 2021-03-17

Family

ID=56117975

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017559428A Active JP6843768B2 (ja) 2015-05-13 2016-05-13 高フェニルアラニン血症を低減させるように操作された細菌
JP2021027597A Active JP7245271B2 (ja) 2015-05-13 2021-02-24 高フェニルアラニン血症を低減させるように操作された細菌
JP2023037515A Active JP7592777B2 (ja) 2015-05-13 2023-03-10 高フェニルアラニン血症を低減させるように操作された細菌

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021027597A Active JP7245271B2 (ja) 2015-05-13 2021-02-24 高フェニルアラニン血症を低減させるように操作された細菌
JP2023037515A Active JP7592777B2 (ja) 2015-05-13 2023-03-10 高フェニルアラニン血症を低減させるように操作された細菌

Country Status (12)

Country Link
US (6) US9889164B2 (cg-RX-API-DMAC7.html)
EP (3) EP3882259B1 (cg-RX-API-DMAC7.html)
JP (3) JP6843768B2 (cg-RX-API-DMAC7.html)
AU (3) AU2016262569B9 (cg-RX-API-DMAC7.html)
BR (1) BR112017024384A2 (cg-RX-API-DMAC7.html)
CA (1) CA2985819A1 (cg-RX-API-DMAC7.html)
ES (2) ES3068132T3 (cg-RX-API-DMAC7.html)
IL (2) IL296538A (cg-RX-API-DMAC7.html)
PL (2) PL3294760T3 (cg-RX-API-DMAC7.html)
SG (1) SG10202003100XA (cg-RX-API-DMAC7.html)
WO (1) WO2016183531A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201707678B (cg-RX-API-DMAC7.html)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106456744A (zh) 2014-04-01 2017-02-22 鲁比厄斯治疗法股份有限公司 用于免疫调节的方法和组合物
US9688967B2 (en) 2014-12-05 2017-06-27 Synlogic, Inc. Bacteria engineered to treat diseases associated with hyperammonemia
US20160206666A1 (en) 2014-12-22 2016-07-21 Synlogic, Inc. Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tighten gut mucosal barrier
WO2016177682A1 (en) 2015-05-06 2016-11-10 Snipr Technologies Limited Altering microbial populations & modifying microbiota
EP3882259B1 (en) 2015-05-13 2026-01-28 Synlogic Operating Company, Inc. Bacteria engineered to reduce hyperphenylalaninemia
EP3294757B1 (en) * 2015-05-13 2023-12-27 Synlogic Operating Company, Inc. Bacteria engineered to treat a disease or disorder
US11883439B2 (en) 2015-05-13 2024-01-30 Synlogic Operating Company, Inc. Bacteria engineered to treat a disease or disorder
US11685925B2 (en) 2015-10-30 2023-06-27 Synlogic Operating Company, Inc. Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
JP6993970B2 (ja) 2015-11-16 2022-02-15 シンロジック オペレーティング カンパニー インコーポレイテッド 高フェニルアラニン血症を低減させるように操作された細菌
US9988624B2 (en) 2015-12-07 2018-06-05 Zymergen Inc. Microbial strain improvement by a HTP genomic engineering platform
US11566238B2 (en) 2016-12-15 2023-01-31 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for modulating growth of a genetically modified gut bacterial cell
WO2018183685A1 (en) * 2017-03-29 2018-10-04 President And Fellows Of Harvard College Methods of regulating gene expression in a cell
US20180362590A1 (en) * 2017-04-14 2018-12-20 Synthetic Genomics, Inc. Polypeptides with type v crispr activity and uses thereof
EP3642221A1 (en) * 2017-06-21 2020-04-29 Synlogic Operating Company, Inc. Bacteria for the treatment of disorders
US11458172B2 (en) 2017-09-08 2022-10-04 New Portal Limited Nucleic acid systems that enable bacteria to specifically target solid tumors via glucose-dependent viability
US10849938B2 (en) 2017-09-13 2020-12-01 ZBiotics Company Gene expression system for probiotic microorganisms
CN107904222B (zh) * 2017-11-30 2019-10-08 江南大学 一种热稳定性提高的l-氨基酸脱氨酶突变体及其构建方法
MX2020005875A (es) 2017-12-05 2020-10-08 Bioplx Inc Métodos y composiciones para prevenir la infección microbiana.
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
JP2022512380A (ja) 2018-12-10 2022-02-03 ノヴォム バイオテクノロジーズ,インコーポレイテッド 高シュウ酸尿症を治療するための方法及び組成物
WO2020132017A1 (en) * 2018-12-20 2020-06-25 University Of South Carolina Pharmabiotic treatments for metabolic disorders
KR20220003030A (ko) * 2019-04-29 2022-01-07 신로직 오퍼레이팅 컴퍼니, 인코포레이티드 살아 있는 세포 계수 기술에 의한 유전적으로 조작된 미생물의 계수
CA3142608A1 (en) 2019-06-04 2020-12-10 Cocoon Biotech Inc. Silk-based products, formulations, and methods of use
WO2020257707A1 (en) * 2019-06-21 2020-12-24 Ginkgo Bioworks, Inc. Biosynthesis of enzymes for use in treatment of maple syrup urine disease (msud)
CN110257291B (zh) * 2019-06-25 2021-07-23 北京大学 一株耐受镍离子毒性的无色杆菌及其应用
CA3156035A1 (en) 2019-09-27 2021-04-01 Intrexon Actobiotics Nv D/B/A Precigen Actobio Treatment of celiac disease
JP2023501539A (ja) 2019-11-12 2023-01-18 アクティム・セラピューティクス・インコーポレイテッド 免疫刺激細菌デリバリープラットフォーム、および治療用産物のデリバリーのためのその使用
JP2023511305A (ja) 2020-01-17 2023-03-17 ウニベルシテ カソリーク デ ルーベン 変化したエンベロープ完全性を有する遺伝子組換え細菌およびその使用
WO2021173808A1 (en) * 2020-02-25 2021-09-02 Synlogic Operating Company, Inc. Recombinant bacteria engineered to treat diseases associated with uric acid and methods of use thereof
WO2021188819A1 (en) 2020-03-20 2021-09-23 Synlogic Operating Company, Inc. Microorganisms engineered to reduce hyperphenylalaninemia
WO2021207647A1 (en) * 2020-04-09 2021-10-14 Computational International LLC Small molecule drugs as targeted therapeutics
US12582709B2 (en) 2020-07-02 2026-03-24 The Regents Of The University Of California Persistent memory T-cell responses to cancer and infectious-disease antigens by manipulation of amino acid-catabolism pathways
WO2022006748A1 (en) 2020-07-07 2022-01-13 New Portal Limited Genetically engineered live bacteria and methods of constructing the same
JP2023539454A (ja) 2020-08-12 2023-09-14 アクティム・セラピューティクス・インコーポレイテッド 免疫刺激細菌ベースのワクチン、治療薬およびrnaデリバリープラットフォーム
US20230332164A1 (en) * 2020-09-30 2023-10-19 Synlogic Operating Company, Inc. Bacteria engineered to secrete active proteins
JP2023546022A (ja) 2020-10-08 2023-11-01 ジーバイオティクス カンパニー 腸内での繊維合成酵素の発現のための操作されたプロバイオティクス
IL302604A (en) * 2020-11-10 2023-07-01 Palena Therapeutics Inc Epitope-Encapsulated Random Peptide (EERP) Preparations for the Treatment of Immune-Mediated Conditions and Methods of Use
AU2021393455A1 (en) 2020-12-02 2023-06-29 Synlogic Operating Company, Inc. Engineered microorganisms
CN112501098B (zh) * 2020-12-11 2023-01-03 上海陶宇晟生物技术有限责任公司 具有降解苯丙氨酸能力的工程益生菌
WO2022146718A1 (en) 2020-12-31 2022-07-07 Synlogic Operating Company, Inc. Microorganisms engineered to reduce hyperphenylalaninemia
CN112662606A (zh) * 2021-01-06 2021-04-16 中国科学院分子植物科学卓越创新中心 用于治疗苯丙酮尿症的工程益生菌
CN112662607B (zh) * 2021-01-07 2026-07-17 上海陶宇晟生物技术有限责任公司 具备表面展示苯丙氨酸解氨酶的工程益生菌
US20240285699A1 (en) * 2021-06-24 2024-08-29 Lonza Greenwood Llc Method to Control Administration of Active Substance to the Digestive Tract
CN117651776A (zh) * 2021-07-16 2024-03-05 株式会社钟化 使用了大肠杆菌的质粒dna的制造方法
WO2023086796A2 (en) 2021-11-09 2023-05-19 Actym Therapeutics, Inc. Immunostimulatory bacteria for converting macrophages into a phenotype amenable to treatment, and companion diagnostic for identifying subjects for treatment
CN116836899A (zh) * 2022-03-02 2023-10-03 和度生物技术(上海)有限公司 一种用于治疗高苯丙氨酸血症的工程微生物及其用途
CN114717172B (zh) * 2022-03-21 2022-09-23 江南大学 合成l-缬氨酸的大肠杆菌及其构建方法与应用
GB202209518D0 (en) 2022-06-29 2022-08-10 Snipr Biome Aps Treating & preventing E coli infections
CN116463362B (zh) * 2023-06-15 2023-09-19 中国中医科学院中药研究所 一种细胞分裂抑制剂的制备方法
WO2025170927A1 (en) * 2024-02-06 2025-08-14 The Cleveland Clinic Foundation Kynurenine responsive bacteria and cancer therapies
WO2026050209A1 (en) * 2024-08-26 2026-03-05 San Diego State Unversity (Sdsu) Foundation, Dba San Diego State University Research Foundation Genetically engineered marine bacteria for biomaterial production, use in aquaculture and marine environmental restoration and methods for making and using them
WO2026085295A1 (en) * 2024-10-16 2026-04-23 The Cleveland Clinic Foundation Kynurenine responsive and degrading bacteria

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9107305D0 (en) 1991-04-08 1991-05-22 Unilever Plc Probiotic
CN1154845A (zh) 1996-09-09 1997-07-23 首都医学院附属北京红十字朝阳医院 能表达活性苯丙氨酸脱氨酶的基因工程菌口服制剂
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6203797B1 (en) 1998-01-06 2001-03-20 Stephen C. Perry Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome
CA2353800A1 (en) 1998-12-02 2000-06-08 Trustees Of Boston University Gene networks for control of gene expression
EP1034787A1 (en) 1999-03-11 2000-09-13 Société des Produits Nestlé S.A. Lactobacillus strains preventing diarrhea caused by pathogenic bacteria
JP4682454B2 (ja) 2000-06-28 2011-05-11 味の素株式会社 新規変異型n−アセチルグルタミン酸合成酵素及びl−アルギニンの製造法
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
CA2446776C (en) 2001-05-03 2011-07-12 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Self-containing lactococcus strain
US7314974B2 (en) 2002-02-21 2008-01-01 Monsanto Technology, Llc Expression of microbial proteins in plants for production of plants with improved properties
US7731976B2 (en) 2003-08-29 2010-06-08 Cobb And Company, Llp Treatment of irritable bowel syndrome using probiotic composition
JP4452914B2 (ja) 2003-09-08 2010-04-21 味の素株式会社 新規トランスポータタンパク質
WO2006069610A2 (en) 2004-07-02 2006-07-06 Metanomics Gmbh Process for the production of fine chemicals
AU2005286763A1 (en) 2004-09-17 2006-03-30 Biomarin Pharmaceutical, Inc. Variants and chemically-modified variants of phenylalanine ammonia-lyase
ZA200704766B (en) 2004-11-30 2008-09-25 Aeras Global Tb Vaccine Found Bacterial packaging strains useful for generation and production of recombinant double-stranded RNA nucleocapsids and uses thereof
GB0501540D0 (en) 2005-01-25 2005-03-02 Univ Leeds Controlled production and delivery of biologically active agents by gut bacteria
EP1869174B1 (en) 2005-03-10 2015-02-18 BASF Enzymes LLC Lyase enzymes, nucleic acids encoding them and methods for making and using them
EP2029739A4 (en) 2006-06-02 2009-11-25 Verenium Corp LYASE ENZYMES, NUCLEIC ACIDS FOR THEIR CODING AND METHOD FOR THEIR PREPARATION AND USE
TW200819540A (en) 2006-07-11 2008-05-01 Genelux Corp Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders
US9084434B2 (en) 2006-09-27 2015-07-21 Little Calumet Holdings Llc Probiotic oral dosage forms
US20100297249A1 (en) 2007-07-05 2010-11-25 North-West University Enhancement of the efficacy of therapeutic proteins
CN101586111B (zh) * 2008-05-22 2012-03-07 北京三元基因工程有限公司 一种活性乳酸乳球菌制品的制备方法
JP2012504116A (ja) 2008-09-29 2012-02-16 アクトジェニックス・エヌブイ 粘膜での微生物のコロニー形成の低減
CA2768428C (en) 2009-08-04 2021-08-17 Evogene Ltd. Isolated polynucleotides and polypeptides, and methods of using same for increasing abiotic stress tolerance, yield, growth rate, vigor, biomass, oil content, and/or nitrogen use efficiency of plants
WO2011080505A2 (en) 2009-12-28 2011-07-07 Bigdna Ltd Method of growing phage for commercial use
RU2603061C2 (ru) 2010-03-02 2016-11-20 Ренессанс Байосайенс Корп., Функциональное улучшение микроорганизмов для минимизации продукции акриламида
US8129170B1 (en) 2010-12-06 2012-03-06 E.I. Du Pont De Nemours And Company Recombinant bacteria having the ability to metabolize sucrose
US9409950B2 (en) 2010-12-23 2016-08-09 Biogen Ma Inc. Linker peptides and polypeptides comprising same
US9017961B2 (en) * 2012-03-05 2015-04-28 E.I. Du Pont De Nemours And Company Recombinant bacteria comprising novel sucrose transporters
FR2990699B1 (fr) 2012-05-21 2016-02-05 Agronomique Inst Nat Rech Cassettes d'expression procaryotes regulees par le stress
US20150337336A1 (en) 2012-06-22 2015-11-26 Phytogene, Inc. Enzymes and methods for styrene synthesis
EP3222288A1 (en) 2012-07-27 2017-09-27 University of North Texas Genetically modified probiotic for the treatment of phenylketonuria (pku) disease
EP2914274A4 (en) * 2012-11-01 2016-07-20 Sydney Children S Hospital Network Randwick And Westmead GENETICALLY MODIFIED PROBIOTIC FOR THE TREATMENT OF PHENYLKETONURIA
JP6419082B2 (ja) 2012-12-13 2018-11-07 マサチューセッツ インスティテュート オブ テクノロジー リコンビナーゼに基づく論理/メモリシステム
US9951340B2 (en) 2013-03-07 2018-04-24 The General Hospital Corporation Compositions and methods for bacterial delivery of polypeptides
PL2986722T3 (pl) 2013-04-18 2019-10-31 Codexis Inc Skonstruowane polipeptydy amoniakoliazy fenyloalaniny
US9688967B2 (en) 2014-12-05 2017-06-27 Synlogic, Inc. Bacteria engineered to treat diseases associated with hyperammonemia
MX383245B (es) * 2014-12-05 2025-03-13 Synlogic Operating Co Inc Bacterias modificadas para tratar enfermedades asociadas con hiperamonemia.
EP3882259B1 (en) * 2015-05-13 2026-01-28 Synlogic Operating Company, Inc. Bacteria engineered to reduce hyperphenylalaninemia
EP3294757B1 (en) 2015-05-13 2023-12-27 Synlogic Operating Company, Inc. Bacteria engineered to treat a disease or disorder
EP3303601B1 (en) 2015-05-28 2022-05-11 Evolva SA Biosynthesis of phenylpropanoids and phenylpropanoid derivatives
EP3307870B1 (en) * 2015-06-10 2023-08-02 Synlogic Operating Company, Inc. Bacteria engineered to treat disorders involving the catabolism of a branched chain amino acid
WO2016210373A2 (en) 2015-06-24 2016-12-29 Synlogic, Inc. Recombinant bacteria engineered for biosafety, pharmaceutical compositions, and methods of use thereof
US20170216370A1 (en) 2015-07-31 2017-08-03 Synlogic, Inc. Bacteria engineered to treat disorders involving propionate catabolism
JP6993970B2 (ja) 2015-11-16 2022-02-15 シンロジック オペレーティング カンパニー インコーポレイテッド 高フェニルアラニン血症を低減させるように操作された細菌
CN109311953A (zh) 2016-06-13 2019-02-05 本森希尔生物系统股份有限公司 使用苯丙氨酸脱氨酶序列增加植物生长和产量
EP3642221A1 (en) 2017-06-21 2020-04-29 Synlogic Operating Company, Inc. Bacteria for the treatment of disorders
EP3820833A4 (en) 2018-07-12 2022-08-03 Codexis, Inc. MODIFIED AMMONIA-LYASE PHENYLALANINE POLYPEPTIDES
WO2021188819A1 (en) 2020-03-20 2021-09-23 Synlogic Operating Company, Inc. Microorganisms engineered to reduce hyperphenylalaninemia
WO2022146718A1 (en) 2020-12-31 2022-07-07 Synlogic Operating Company, Inc. Microorganisms engineered to reduce hyperphenylalaninemia
WO2023044479A1 (en) 2021-09-17 2023-03-23 Synlogic Operating Company, Inc. Methods for reducing hyperphenylalaninemia

Similar Documents

Publication Publication Date Title
US11896627B2 (en) Bacteria engineered to treat metabolic diseases
US20220233609A1 (en) Bacteria engineered to treat disorders in which oxalate is detrimental
EP3307870B1 (en) Bacteria engineered to treat disorders involving the catabolism of a branched chain amino acid
CN112041427B (zh) 合生元组合物
ES2881384T3 (es) Bacterias manipuladas para reducir la hiperfenilalaninemia
AU2015357549B2 (en) Bacteria engineered to treat diseases associated with hyperammonemia
US20180273956A1 (en) Bacteria Engineered to Treat Diseases that Benefit from Reduced Gut Inflammation and/or Tighten Gut Mucosal Barrier
Watson et al. Enhancing bile tolerance improves survival and persistence of Bifidobacterium and Lactococcus in the murine gastrointestinal tract
CA3066085A1 (en) Bacteria for the treatment of disorders
JP6817966B2 (ja) 高アンモニア血症に関連する疾患を治療するために操作された細菌
AU2016226234A1 (en) Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
WO2016183532A1 (en) Bacteria engineered to treat a disease or disorder
WO2022121968A1 (zh) 具有降解苯丙氨酸能力的工程益生菌
Alexander et al. Exploiting prophage-mediated lysis for biotherapeutic release by Lactobacillus reuteri
WO2017123592A1 (en) Bacteria engineered to treat disorders associated with bile salts
US20230105474A1 (en) Recombinant bacteria engineered to treat diseases associated with uric acid and methods of use thereof
JP2018521674A5 (cg-RX-API-DMAC7.html)
US20230090705A1 (en) Recombinant bacteria engineered to treat diseases associated with methionine metabolism and methods of use thereof
WO2022148362A1 (zh) 具备表面展示苯丙氨酸解氨酶的工程益生菌
US11458172B2 (en) Nucleic acid systems that enable bacteria to specifically target solid tumors via glucose-dependent viability
CA3140174A1 (en) Synergistic combinations of arginine-producing bacteria and/or ammonia-consuming bacteria and checkpoint inhibitors and methods of use thereof
Guo et al. Developing the Limosilactobacillus reuteri chassis through an endogenous programmable endonuclease-based genome editing tool
US20240110191A1 (en) Engineered microorganisms
Steidler et al. In situ delivery of therapeutic proteins by recombinant Lactococcus lactis
Watson et al. Enhancing bile tolerance improves survival and persistence of